The potential of erdosteine to reduce the rate of exacerbations of chronic obstructive pulmonary disease
https://doi.org/10.18093/0869-0189-2022-32-2-253-259
Abstract
Exacerbations of COPD worsen health status, increase the frequency of hospitalizations, the likelihood of disease progression, and the risk of adverse outcomes. One of the main goals of the treatment of stable COPD today is to reduce the frequency of exacerbations of the disease. Thus, the expansion of suitable therapeutic options is extremely relevant for clinical practice. Use of mucolytic drugs with antioxidant and anti-inflammatory effects in COPD is justified by the pathogenetic mechanisms. These drugs are able to reduce the frequency of exacerbations, among other positive effects.
Aim. This article describes additional possibilities of pharmacotherapy using the mucoactive drug erdosteine as maintenance therapy for COPD aimed at preventing exacerbations of this disease.
Conclusion. The use of erdosteine in patients with stable COPD helps reduce the frequency and duration of exacerbations of the disease, primarily in the patients with stage II according to GOLD.
Supporting agencies: The article was published with the financial support of LLC “CSC Ltd Russia”. LLC “CSC Ltd Russia” is not responsible for the content of the article. The opinion of LLC “CSC Ltd Russia” may differ from the opinion of the authors and editors of the article. The article was prepared with the financial support of LLC “CSC Ltd Russia”, an organization representing the original erdostein on the Russian market.
About the Authors
S. N. Avdeev
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University);
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Sergey N. Avdeev, Doctor of Medicine, Professor, Corresponding Member of Russian Academy of Sciences, Head of the Department of Pulmonology, N.V.Sklifosovsky Institute of Clinical Medicine, I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Head of the Clinical Department, Federal Pulmonology Research Institute
SPIN-code: 1645-5524
ul. Trubetskaya 8, build. 2, Moscow, 119991, Russia;
Orehovyy bul. 28, Moscow, 115682, Russia
N. V. Trushenko
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University);
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Natal’ya V. Trushenko, Candidate of Medicine, Assistant, Department of Pulmonology, N.V.Sklifosovsky Institute of Clinical Medicine, I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Researcher, Scientific and Methodological Center for Monitoring and Control of Respiratory Diseases, Federal Pulmonology Research Institute
ul. Trubetskaya 8, build. 2, Moscow, 119991, Russia;
Orehovyy bul. 28, Moscow, 115682, Russia
S. Yu. Chikina
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
Svetlana Yu. Chikina, Candidate of Medicine, Assistant Lecturer, Department of Pulmonology, N.V.Sklifosovsky Institute of Clinical Medicine, I.M.Sechenov First Moscow State Medical University
ul. Trubetskaya 8, build. 2, Moscow, 119991, Russia
O. A. Suvorova
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
Olga A. Suvorova, 1st year Resident of Department of Pulmonology, N.V.Sklifosovsky Institute of Clinical Medicine, I.M.Sechenov First Moscow State Medical University
ul. Trubetskaya 8, build. 2, Moscow, 119991, Russia
References
1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2022 Report. Available at: https://goldcopd.org/2022-gold-reports-2/
2. Aisanov Z., Avdeev S., Arkhipov V. et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 183–187. DOI: 10.2147/copd.s153770.
3. Wilkinson T.M.A., Donaldson G.C., Hurst J.R. et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 169 (12): 1298–1303. DOI: 10.1164/rccm.200310-1443OC.
4. Vijayasaratha K., Stockley R.A. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest. 2008; 133 (1): 34–41. DOI: 10.1378/chest.07-1692.
5. Aaron S.D., Donaldson G.C., Whitmore G.A. et al. Time course and pattern of COPD exacerbation onset. Thorax. 2012; 67 (3): 238–243. DOI: 10.1136/thoraxjnl-2011-200768.
6. Perera W.R., Hurst J.R., Wilkinson T.M.A. et al. Infl tory changes, recovery and recurrence at COPD exacerbation. Eur. Respir. J. 2007; 29 (3): 527–534. DOI: 10.1183/09031936.00092506.
7. Donaldson G.C., Law M., Kowlessar B. et al. Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2015; 192 (8): 943–950. DOI: 10.1164/rccm.201412-2269OC.
8. Avdeev S.N., Trushenko N.V., Gaynitdinova V.V. et al. [Treatment of exacerbations of chronic obstructive pulmonary disease]. Terapevticheskiy arkhiv. 2018; 90 (12): 68–75. DOI: 10.26442/00403660.2018.12.000011 (in Russian).
9. Seemungal T.A., Donaldson G.C., Bhowmik A. et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161 (5): 1608–1613. DOI: 10.1164/ajrccm.161.5.9908022.
10. Zheng J.P., Wen F.Q., Bai C.X. et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 2014; 2 (3): 187–194. DOI: 10.1016/S2213-2600(13)70286-8.
11. Zheng J.P., Kang J., Huang S.Q. et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008; 371 (9629): 2013–2018. DOI: 10.1016/S0140-6736(08)60869-7.
12. Cazzola M., Rogliani P., Calzetta L. et al. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. COPD. 2017; 14 (5): 552‒563. DOI: 10.1080/15412555.2017.1347918.
13. Papi A., Avdeev S., Calverley P.M.A. et al. Use of mucolytics in COPD: a Delphi consensus study. Respir. Med. 2020; 175: 106190. DOI: 10.1016/j.rmed.2020.106190.
14. Rogers D.F. Mucoactive agents for airway mucus hypersecretory diseases. Respir. Care. 2007; 52 (9): 1176–1197. Available at: http://rc.rcjournal.com/content/52/9/1176
15. Zuin R., Palamidese A., Negrin R. et al. High dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin. Drug Invest. 2005; 25 (6): 401–408. DOI: 10.2165/00044011-200525060-00005.
16. Moretti M. Pharmacology and clinical effi acy of erdosteine in chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 2007; 1 (3): 307–316. DOI: 10.1586/17476348.1.3.307.
17. Hotzinger H. Erdosteine or placebo combined with co-trimoxazole in the treatment of hypersecretive infectious bronchitis: a double blind clinical trial. Med. Praxis. 1991; 12: 171–181.
18. Zanasi A., Menarini A. Erdosteine versus N-acetylcysteine in the treatment of exacerbation of chronic bronchopneumopathies. Med. Praxis. 1991; 12: 207–217.
19. Ghiringhelli G. Cross-over study of efficacy and tolerability of erdosteine in the treatment of chronic obstructive bronchial disease in stable hypersecretive phase: controlled double-blind study vs placebo. Arch. Med. Int. 1995; 47 (4): 113–120.
20. Moretti M. Erdosteine: its relevance in COPD treatment. Expert Opin. Drug Metab. Toxicol. 2009; 5 (3): 333–343. DOI: 10.1517/17425250902814790.
21. Dal Negro R.W., Visconti M., Micheletto C., Tognella S. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD. Pulm. Pharmacol. Ther. 2008; 21 (2): 304–308. DOI: 10.1016/j.pupt.2007.07.004.
22. Braga P. Bacterial adhesion to human cells. In: Edi-Aipo Scientifica. Pisa; 2000: 1–63.
23. Ricevuti G., Nazzone A., Uccelli E. et al. Influence of erdosteine, a mucolytic agent, on amoxicillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis. Thorax. 1988; 43 (8): 585–590. DOI: 10.1136/thx.43.8.585.
24. Moretti M., Bottrighi P., Dallari R. et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Exp. Clin. Res. 2004; 30 (4): 143–152.
25. Cazzola M., Floriani I., Page C.P. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. Pulm. Pharmacol. Ther. 2010; 23 (2): 135–144. DOI: 10.1016/j.pupt.2009.10.002.
26. Decramer M., Rutten-van Mölken M., Dekhuijzen P.N.R. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005; 365 (9470): 1552–1560. DOI: 10.1016/S0140-6736(05)66456-2.
27. Jenkins C.R., Postma D.S., Anzueto A.R. et al. Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm. Med. 2015; 15: 97. DOI: 10.1186/s12890-015-0077-0.
28. Braga P.C., Dal Sasso M., Sala M., Gianelle V. Effects of erdosteine and its metabolites on bacterial adhesiveness. Arzneimittelforschung. 1999; 49 (4): 344–350. DOI: 10.1055/s-0031-1300425.
29. Dal Negro R.W., Wedzicha J.A., Iversen M. et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur. Respir. J. 2017; 50 (4): 1700711. DOI: 10.1183/13993003.00711-2017.
30. Calverley P.M., Page C., Dal Negro R.W. et al. Effect of erdosteine on COPD exacerbations in COPD patients with moderate airflow limitation. Int. J. Chron. Obstruct. Pulmon. Dis. 2019; 14: 2733–2744. DOI: 10.2147/COPD.S221852.
31. Jenkins C.R., Jones P.W., Calverley P.M. et al. Effiacy of salmeterol/ fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir. Res. 2009; 10 (1): 59. DOI: 10.1186/1465-9921-10-59.
32. Cazzola M., Page C., Roglisni P. et al. Multifaceted beneficial effects of erdosteine: more than a mucolytic agent. Drugs. 2020; 80 (17): 1799–1809. DOI: 10.1007/s40265-020-01412-x.
33. Rogliani P.R., Matera M.G., Page C. et al. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine and N-acetylcysteine. Respir. Res. 2019; 20 (1): 104. DOI: 10.1186/s12931-019-1078-y.
34. Wedzicha J.A., Banerji D., Chapman K.R. et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI: 10.1056/nejmoa1516385.
35. Martinez F.J., Vestbo J., Anderson J. et al. Eff of flicasone furoate and vilanterol on exacerbations of COPD in patients with moderate airflow obstruction. Am. J. Respir. Crit. Care Med. 2017; 195 (7): 881–888. DOI: 10.1164/rccm.201607-1421OC.
Review
For citations:
Avdeev S.N., Trushenko N.V., Chikina S.Yu., Suvorova O.A. The potential of erdosteine to reduce the rate of exacerbations of chronic obstructive pulmonary disease. PULMONOLOGIYA. 2022;32(2):253-259. (In Russ.) https://doi.org/10.18093/0869-0189-2022-32-2-253-259
Views:
898
Email this article 